Georg Jeryczynski
YOU?
Author Swipe
View article: Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study
Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study Open
Background: Belantamab mafodotin (belamaf) is a BCMA-targeting antibody–drug conjugate used in triple-class refractory multiple myeloma. Despite its efficacy, keratopathy remains a significant dose-limiting toxicity. Following its withdraw…
View article: Prediction of 90-day mortality risk after unplanned emergency department visits of advanced stage cancer patients
Prediction of 90-day mortality risk after unplanned emergency department visits of advanced stage cancer patients Open
Purpose Cancer represents the leading cause of mortality in high-income countries. In the last years, the rate of emergency department (ED) visits by cancer patients has increased 5.5-fold. These ED visits impose a significant economic bur…
View article: A case of fungal peritonitis in a patient with paramalignant ascites
A case of fungal peritonitis in a patient with paramalignant ascites Open
View article: Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome
Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome Open
In summary, our data suggests, that a rapid start with systemic hematologic treatment in patients with MM and CN is crucial and achieving an early hematologic response is important for renal recovery. Moreover, achieving a deep hematologic…
View article: The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients Open
View article: Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy
Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy Open
View article: Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM Open
The treatment landscape for relapsed multiple myeloma (RRMM) has experienced an unprecedented wave of innovation. Implementation of numerous new substances and drug classes with different modes of action is made possible in routine clinica…
View article: Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre
Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre Open
Background We investigated the influence of population‐wide COVID‐19 lockdown measures implemented on 16, March 2020 on routine and emergency care of cancer outpatients at a tertiary care cancer centre in Vienna, Austria. Methods We compar…
View article: First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience Open
Daratumumab proved to be highly effective in newly diagnosed AL amyloidosis with excellent hematologic and organ response rates, a remarkable safety profile, and good tolerability even in patients with advanced stage of disease.
View article: Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up
Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up Open
Summary Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant hematological condition arising from B‑cells, characterized by the presence of monoclonal immunoglobulin production, also known as paraprotein. It is found…
View article: ASH 2018—Highlights in Multiple Myeloma
ASH 2018—Highlights in Multiple Myeloma Open
More than 900 abstracts on multiple myeloma were presented at this year's ASH in San Diego. Several trials explored the addition of the monoclonal antibody daratumumab to established treatment regimens in both newly diagnosed as well as re…
View article: Gender specific aspects in patients with mantle cell lymphoma undergoing rituximab-based therapy – what role does gender play?
Gender specific aspects in patients with mantle cell lymphoma undergoing rituximab-based therapy – what role does gender play? Open
View article: Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data Open
View article: Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study Open
View article: Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease
Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease Open
The 2016 revised WHO criteria for the diagnosis of pre‐fibrotic/early primary myelofibrosis (pre‐PMF) require at least one of the following four borderline expressed minor clinical criteria: anemia, leukocytosis, elevated lactate dehydroge…
View article: Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria Open
View article: Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’
Response to Harrison et al. ‘Clinically relevant differences between BCSH and WHO diagnostic criteria for ET’ Open
View article: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria Open